SVRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Savara Inc. (SVRA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including FDA priority review for its Molbreevi therapy, insider buying activity, and bullish technical indicators. Despite a lack of immediate AI or SwingMax trading signals, the long-term potential and positive sentiment make it a suitable investment.
The technical indicators for SVRA are bullish. The MACD is positive and expanding, the RSI is neutral at 67.489, and moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 5.981), indicating potential upward momentum.
FDA has granted priority review for Molbreevi with a decision expected by August 22,
Insider buying activity has increased significantly (373.33% over the last month).
Analyst Andrew Fein has raised the price target to $10 from $8, maintaining a Buy rating.
Bullish technical indicators suggest upward momentum.
The company is still in a pre-revenue phase with no revenue growth.
Net income remains negative, though improving.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income of -$29.56M, which improved by 21.91% YoY. EPS increased to -0.14, up 27.27% YoY, indicating progress in reducing losses.
Analyst Andrew Fein from H.C. Wainwright raised the price target to $10 from $8 and reiterated a Buy rating, citing the company's strong positioning ahead of Molbreevi's potential launch.
